Sign in

Private company

Locus Biosciences

Clinical phase American pharmaceutical company

Locus Biosciences (Locus) is a clinical-stage pharmaceutical company based in Morrisville (Research Triangle Park), North Carolina, founded in 2015 as an NCSU spin‑out. It develops CRISPR-Cas3–enhanced bacteriophage therapies (“crPhage”) targeting drug-resistant bacterial infections.2 Wikipedia text CC BY-SA 4.0

Last updated Oct 21, 2026.

Overview

Jan 1, 1998Founded1

See how the biggest companies compare on our leaderboards

Locus Biosciences (Locus) is a clinical-stage pharmaceutical company based in Morrisville (Research Triangle Park), North Carolina, founded in 2015 as an NCSU spin‑out. It develops CRISPR-Cas3–enhanced bacteriophage therapies (“crPhage”) targeting drug-resistant bacterial infections.2

Timeline

  1. Jan 1, 1998Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Jun 2027Phase 2 trial readout expected Phase 2 trial of LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose and others in Urinary Tract Infections: primary completion expected Jun 2027 (ClinicalTrials.gov NCT05488340).3

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$87.1M 2020–2026
Money received by yearMoney received by year, 2020–2026: $87.1M in all. Federal contracts $87.1M.$0$10M$20M$30M2020 · Federal contracts: $11.0M20202022 · Federal contracts: $6.2M20222023 · Federal contracts: $7.8M2024 · Federal contracts: $23.9M20242025 · Federal contracts: $28.3M2026 · Federal contracts: $9.8M2026
Figures by year
YearFederal contractsTotal
2026$9.8M$9.8M
2025$28.3M$28.3M
2024$23.9M$23.9M
2023$7.8M$7.8M
2022$6.2M$6.2M
2020$11.0M$11.0M

Federal awards

Obligated amounts from USAspending.gov4, by calendar year, 2020–2026, for its registration. Obligations are what agencies committed, not always what was paid out. Contracts pay for goods and services; grants, loans and direct payments are assistance. Loans are charted at the face value of the loans listed here. An award’s amount below is its lifetime total, and some began before the years charted.

Largest contracts

  1. Sep 28, 2020$73.9M from Office of Assistant Secretary for Preparedness and Response: Clinical development of crispr-cas3 phage cocktail for the treatment of recurrent urinary tract infections caused by escherichia coli includ5 To LOCUS BIOSCIENCES INC Award 75A50120C00169
  2. Sep 24, 2025$13.2M from National Institutes of Health: Advance a novel therapeutic to a first-in-human clinical study6 To LOCUS BIOSCIENCES INC Award 75N93025C00035

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6